Drug Insights

Strategically Search Citalopram on Synapse: A How-to Guide

9 February 2024
2 min read

Citalopram was approved for medical use in the United States in 1998. It is on the World Health Organization's List of Essential Medicines. Citalopram, sold under the brand name Celexa among others, is an antidepressant of the selective serotonin reuptake inhibitor (SSRI) class. It is used to treat major depressive disorder, obsessive compulsive disorder, panic disorder, and social phobia. The antidepressant effects may take one to four weeks to occur. It is taken by mouth. Common side effects include nausea, trouble sleeping, sexual problems, shakiness, feeling tired, and sweating. Serious side effects include an increased risk of suicide in those under the age of 25, serotonin syndrome, glaucoma, and QT prolongation. Antidepressant discontinuation syndrome or persistent Post-SSRI sexual dysfunction may occur when stopped. Click on the image below to begin the exploration journey of Citalopram through the Synapse database!

图形用户界面, 文本, 应用程序, 电子邮件

描述已自动生成

You can search for the latest pharmaceutical information such as drugs, targets, patents, transactions, clinical results, etc. through the Synapse database. Come and experience it!

图形用户界面, 文本, 应用程序, 聊天或短信

描述已自动生成

FDA Approves CellVax's FK-PC101 IND Submission for Personalized Cancer Immunotherapy
Latest Hotspot
3 min read
FDA Approves CellVax's FK-PC101 IND Submission for Personalized Cancer Immunotherapy
9 February 2024
CellVax Therapeutics has received approval from the FDA for its IND submission for FK-PC101, a new individualized immunotherapy treatment for cancer.
Read →
User-friendly Guide to Find Clonidine on Synapse
Drug Insights
2 min read
User-friendly Guide to Find Clonidine on Synapse
9 February 2024
Clonidine lowers blood pressure by stimulating α2 receptors in the brain, which results in relaxation of many arteries.
Read →
DP Tech Unveils Kv1.3 Blocker Candidate for IBD and AD Treatment
Latest Hotspot
3 min read
DP Tech Unveils Kv1.3 Blocker Candidate for IBD and AD Treatment
9 February 2024
DP Tech has revealed its selection of a developmental contender, a promising top-tier Kv1.3 blocker aimed at tackling immune disorders like IBD and AD.
Read →
Harnessing Synapse for Montelukast Information: Strategies and Tips
Drug Insights
2 min read
Harnessing Synapse for Montelukast Information: Strategies and Tips
9 February 2024
SINGULAIR® (Montelukast sodium) is a drug for treating asthma, exercise-induced bronchoconstriction (EIB), and allergic rhinitis.
Read →
Get started for free today!
Accelerate Strategic R&D decision making with Synapse, PatSnap’s AI-powered Connected Innovation Intelligence Platform Built for Life Sciences Professionals.
Start your data trial now!
Synapse data is also accessible to external entities via APIs or data packages. Empower better decisions with the latest in pharmaceutical intelligence.